Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Moves Forward With Odanacatib Filing; FDA Accepts MK-3475 Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

At a May 6 investor day, Merck’s R&D head Roger Perlmutter revealed the safety issues that have been delaying the company’s late-stage osteoporosis drug and tried to renew confidence in the treatment.


Related Content

Merck Bets Big On Oncology In New R&D Strategy
Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis
With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012
Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts